{
  "title": "Mieloma Múltiple: Actualización 2024 (S. Vincent Rajkumar, Am J Hematol)",
  "guid": "5209EB0272CF779657C0A3D7",
  "filepath": "/sessions/bold-jolly-cerf/mnt/Dropbox/- Esquemas/- Entidades clínicas/Hematología/Paper. Mieloma Múltiple Actualización-2025.smmx",
  "root": {
    "id": "0",
    "parent": "-1",
    "text": "Mieloma Múltiple: Actualización 2024\n(S. Vincent Rajkumar, Am J Hematol)",
    "guid": "cfKB5Weoy7wE0E3PQSX_qg",
    "children": [
      {
        "id": "1",
        "parent": "0",
        "text": "- Descripción General\nde la Enfermedad",
        "guid": "",
        "children": [
          {
            "id": "2",
            "parent": "1",
            "text": "› Epidemiología",
            "guid": "WuQ8P1voRjp0nR9wUc13gw",
            "children": [
              {
                "id": "3",
                "parent": "2",
                "text": "◊ 1% de todos los cánceres",
                "guid": "T9BLE109afwxWzaXAfG-5g",
                "children": []
              },
              {
                "id": "4",
                "parent": "2",
                "text": "◊ ~10% de malignidades hematológicas",
                "guid": "BhXlyjh0eE8TexZheAhnrw",
                "children": []
              },
              {
                "id": "5",
                "parent": "2",
                "text": "◊ Incidencia EEUU: ~35,000 casos/año; ~13,000 muertes/año",
                "guid": "IB1ECxhLZDA5LmdZaMF_mg",
                "children": []
              },
              {
                "id": "6",
                "parent": "2",
                "text": "◊ Incidencia estable: ~4 por 100,000",
                "guid": "Gs_PuUbDEl9GohFbWYrmJg",
                "children": []
              },
              {
                "id": "7",
                "parent": "2",
                "text": "◊ Más común en hombres",
                "guid": "FSqtrB5qz_RoX3OtZmlu1A",
                "children": []
              },
              {
                "id": "8",
                "parent": "2",
                "text": "◊ Doble incidencia en Afroamericanos vs Caucásicos",
                "guid": "OZsEJgg8tBJybkdnNGSxfA",
                "children": []
              },
              {
                "id": "9",
                "parent": "2",
                "text": "◊ Edad media al diagnóstico: ~65 años",
                "guid": "QrcZHiBUSj0y5l78HZtVXQ",
                "children": []
              }
            ]
          },
          {
            "id": "10",
            "parent": "1",
            "text": "› Manifestaciones\nClínicas Principales",
            "guid": "fDyQdyeDfm1vaMzgTAzbig",
            "children": [
              {
                "id": "11",
                "parent": "10",
                "text": "◊ ★ Enfermedad Ósea",
                "guid": "BMDoaSDEA3dN_ppwCtbOMw",
                "children": [
                  {
                    "id": "12",
                    "parent": "11",
                    "text": "• Lesiones osteolíticas sin neoformación ósea",
                    "guid": "WTh7x2F5sNEC3zXieVW_0g",
                    "children": []
                  },
                  {
                    "id": "13",
                    "parent": "11",
                    "text": "• Principal causa de morbilidad",
                    "guid": "ecUVATwNnTtiFz9tFJTkuw",
                    "children": []
                  },
                  {
                    "id": "14",
                    "parent": "11",
                    "text": "• Detección: TC de baja dosis de cuerpo entero (WB-CT), PET/CT con FDG, RM",
                    "guid": "AtCvmii5UMhuH8rhF_tdRw",
                    "children": []
                  }
                ]
              },
              {
                "id": "15",
                "parent": "10",
                "text": "◊ Anemia",
                "guid": "RyQgvFZ_Po5-ZMwbAL8k4g",
                "children": []
              },
              {
                "id": "16",
                "parent": "10",
                "text": "◊ Hipercalcemia",
                "guid": "XrvyoHDTE4I1I9ZeIXMLvg",
                "children": []
              },
              {
                "id": "17",
                "parent": "10",
                "text": "◊ Insuficiencia Renal",
                "guid": "ESddv2gKNVs_DmEbDWPuNg",
                "children": []
              },
              {
                "id": "18",
                "parent": "10",
                "text": "◊ Aumento del riesgo de infecciones",
                "guid": "D42zyC53LftZcMnBFE6cMQ",
                "children": []
              },
              {
                "id": "19",
                "parent": "10",
                "text": "◊ Enfermedad Extramedular\n(EMD)",
                "guid": "TzsxcydvZDEfJWpkKHOtOg",
                "children": [
                  {
                    "id": "20",
                    "parent": "19",
                    "text": "• ~1-2% al diagnóstico inicial",
                    "guid": "COkVAyIEoEYhyW0MAq4qBA",
                    "children": []
                  },
                  {
                    "id": "21",
                    "parent": "19",
                    "text": "• ~8% desarrollan EMD posteriormente",
                    "guid": "XhI9gQPgrHkXQw6_YOLtGw",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "22",
            "parent": "1",
            "text": "› Estadios Pre-malignos\nAsintomáticos",
            "guid": "LJn9QQVi2aB43kpic74d_Q",
            "children": [
              {
                "id": "23",
                "parent": "22",
                "text": "◊ ★ Gammapatía Monoclonal de\nSignificado Incierto (MGUS)",
                "guid": "W-IYLndDFn10fULgOp4Kzw",
                "children": [
                  {
                    "id": "24",
                    "parent": "23",
                    "text": "• Precede a casi todos los casos de Mieloma Múltiple",
                    "guid": "aBYqACmhGT5cERaNeT2Hvw",
                    "children": []
                  },
                  {
                    "id": "25",
                    "parent": "23",
                    "text": "• Prevalencia: ~5% >50 años",
                    "guid": "EatOmRsfd6kGoXX2ITkCYQ",
                    "children": []
                  },
                  {
                    "id": "26",
                    "parent": "23",
                    "text": "• Prevalencia ~doble en raza negra",
                    "guid": "SZalpGASP7c1h56SGNHXFw",
                    "children": []
                  },
                  {
                    "id": "27",
                    "parent": "23",
                    "text": "• Progresión a Mieloma o malignidad relacionada: ~1% por año",
                    "guid": "B4Gj6FStCPZBRYRREGq46w",
                    "children": []
                  },
                  {
                    "id": "28",
                    "parent": "23",
                    "text": "• Muchos diagnosticados ya tenían MGUS por >10 años",
                    "guid": "drGpPGMO8V4TGOLwVMPmvQ",
                    "children": []
                  },
                  {
                    "id": "29",
                    "parent": "23",
                    "text": "• Factores de riesgo de progresión: **t(4:14)**, **del(17p)**, **gain(1q)**",
                    "guid": "Zu-d1ypb8a81ptPZE4mbGQ",
                    "children": []
                  }
                ]
              },
              {
                "id": "30",
                "parent": "22",
                "text": "◊ ★ Mieloma Múltiple Asintomático\n(Smoldering Multiple Myeloma - SMM)",
                "guid": "L77LUC6FHjsHR7kWC6Djfg",
                "children": [
                  {
                    "id": "31",
                    "parent": "30",
                    "text": "• Estadio intermedio",
                    "guid": "Jcg0uXvE-_ZGPu5NDd5euQ",
                    "children": []
                  },
                  {
                    "id": "32",
                    "parent": "30",
                    "text": "• Prevalencia: ~0. 5% >40 años",
                    "guid": "JWYVNSJQBNsHG-Z4NxFjzg",
                    "children": []
                  },
                  {
                    "id": "33",
                    "parent": "30",
                    "text": "• Tasa de progresión\na Mieloma:",
                    "guid": "RCxu7xjU2-kt9J2zKxwMxw",
                    "children": [
                      {
                        "id": "34",
                        "parent": "33",
                        "text": "• ~10% anual (primeros 5 años)",
                        "guid": "PW98hA29XG5YSmYwBwYiKA",
                        "children": []
                      },
                      {
                        "id": "35",
                        "parent": "33",
                        "text": "• ~3% anual (siguientes 5 años)",
                        "guid": "bc-cJQ3SBMIf1_lAdVFADg",
                        "children": []
                      },
                      {
                        "id": "36",
                        "parent": "33",
                        "text": "• ~1.5% anual (posteriormente)",
                        "guid": "Yn8NuWEdfZEFu_j5WTC29Q",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "37",
                    "parent": "30",
                    "text": "• Factores de riesgo de progresión: Carga tumoral, citogenética (**t(4:14)**, **del(17p)**, **gain(1q)**)",
                    "guid": "QzDNmWObcYw-pafgcu-Y6Q",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "38",
        "parent": "0",
        "text": "- Diagnóstico (Criterios revisados\n**IMWG** - **Rajkumar et al., 2014**)",
        "guid": "",
        "children": [
          {
            "id": "39",
            "parent": "38",
            "text": "› Requisitos\nFundamentales:",
            "guid": "EiCPx0XtYPZ-kHxnN-jEgA",
            "children": [
              {
                "id": "40",
                "parent": "39",
                "text": "◊ ≥10% de células plasmáticas clonales en médula ósea O",
                "guid": "QbJc7UTParVFxyM5ZxhyIg",
                "children": []
              },
              {
                "id": "41",
                "parent": "39",
                "text": "◊ Plasmocitoma probado por biopsia (óseo o extramedular)",
                "guid": "Zx9vkEzjCbIeKdXwJI7sFA",
                "children": []
              }
            ]
          },
          {
            "id": "42",
            "parent": "38",
            "text": "› ★ Y Uno o más Eventos\nDefinitorios de Mieloma (MDE):",
            "guid": "WqBmIHZ0PCArlQ48SHACRg",
            "children": [
              {
                "id": "43",
                "parent": "42",
                "text": "◊ CRAB (atribuible al trastorno\nde células plasmáticas):",
                "guid": "BEZA40ttB3w9wUJUZsVOnA",
                "children": [
                  {
                    "id": "44",
                    "parent": "43",
                    "text": "• Hipercalcemia: Calcio sérico >0.25 mmol/L (>1 mg/dL) sobre el límite normal o >2.75 mmol/L (>11 mg/dL)",
                    "guid": "LIqFDkN9O00_9gWRcLbz_Q",
                    "children": []
                  },
                  {
                    "id": "45",
                    "parent": "43",
                    "text": "• Insuficiencia Renal: Clearance de creatinina <40 mL/min o creatinina sérica >177 µmol/L (>2 mg/dL)",
                    "guid": "XFIXN23qo0Qb0wDEH4Lk0A",
                    "children": []
                  },
                  {
                    "id": "46",
                    "parent": "43",
                    "text": "• Anemia: Hemoglobina >2 g/dL bajo el límite normal o <10 g/dL",
                    "guid": "UYYU0Fp4qKQScn25Y6akmA",
                    "children": []
                  },
                  {
                    "id": "47",
                    "parent": "43",
                    "text": "• Lesiones Óseas: ≥1 lesión osteolítica en radiografía, TC o PET-CT",
                    "guid": "IGYJmxEC-iAbj2kYYhhmiA",
                    "children": []
                  }
                ]
              },
              {
                "id": "48",
                "parent": "42",
                "text": "◊ Biomarcadores (con ~80% riesgo de\nprogresión a daño orgánico sintomático):",
                "guid": "VdJk1WFWjFJJMNiqPPHUZQ",
                "children": [
                  {
                    "id": "49",
                    "parent": "48",
                    "text": "• ≥60% de células plasmáticas clonales en médula ósea",
                    "guid": "LjmWBGdarpphgMB5CNn8JA",
                    "children": []
                  },
                  {
                    "id": "50",
                    "parent": "48",
                    "text": "• Ratio de cadenas ligeras libres (FLC) séricas (involucrada/no involucrada) ≥100\n(FLC involucrada ≥100 mg/L y proteína monoclonal urinaria ≥200 mg/24h)",
                    "guid": "Xc7quw0VzrZRSf5qYhUrng",
                    "children": []
                  },
                  {
                    "id": "51",
                    "parent": "48",
                    "text": "• >1 lesión focal en RM (≥5 mm)",
                    "guid": "WILWMg8LQL5I2no6BQ1bQA",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "52",
            "parent": "38",
            "text": "› Estudios Diagnósticos\nEsenciales",
            "guid": "Uoh8DAjQf8t1xE8-LtqTQw",
            "children": [
              {
                "id": "53",
                "parent": "52",
                "text": "◊ Detección de\nProteína M:",
                "guid": "drsjEBGXUAJOXXgTSEE34A",
                "children": [
                  {
                    "id": "54",
                    "parent": "53",
                    "text": "• Electroforesis de proteínas séricas (SPEP)",
                    "guid": "bA_4p2DP9cwr59x4DHYCQg",
                    "children": []
                  },
                  {
                    "id": "55",
                    "parent": "53",
                    "text": "• Inmunofijación sérica (SIFE)",
                    "guid": "cdLv7Ed3RZFujmjKR6VUwg",
                    "children": []
                  },
                  {
                    "id": "56",
                    "parent": "53",
                    "text": "• Ensayo de cadenas ligeras libres (FLC) séricas",
                    "guid": "KM3R4ze_QXQElyknVwdn5w",
                    "children": []
                  },
                  {
                    "id": "57",
                    "parent": "53",
                    "text": "• ~2% son no secretores verdaderos",
                    "guid": "HxnwDmYX6aFf4WQLfOjayQ",
                    "children": []
                  }
                ]
              },
              {
                "id": "58",
                "parent": "52",
                "text": "◊ Estudios de\nMédula Ósea:",
                "guid": "cy24VzErYnZe_gZnS7COiQ",
                "children": [
                  {
                    "id": "59",
                    "parent": "58",
                    "text": "• Examen morfológico (≥10% células plasmáticas clonales)",
                    "guid": "QDajNCfYgKFQvenKEr8fQA",
                    "children": []
                  },
                  {
                    "id": "60",
                    "parent": "58",
                    "text": "• ★ FISH (Hibridación in\nsitu fluorescente):",
                    "guid": "YwR9Zz8t7L0qP2URC9JPSg",
                    "children": [
                      {
                        "id": "61",
                        "parent": "60",
                        "text": "◊ **t(11:14)**, **t(4:14)**, **t(14:16)**, **t(6:14)**, **t(14:20)**",
                        "guid": "MKkAbUaCOQhBmbKDJ2QjfQ",
                        "children": []
                      },
                      {
                        "id": "62",
                        "parent": "60",
                        "text": "◊ Trisomías",
                        "guid": "WBmJCg_3KpZvpVtdRCmBsQ",
                        "children": []
                      },
                      {
                        "id": "63",
                        "parent": "60",
                        "text": "◊ **del(17p)**",
                        "guid": "cMcgYhuNN9ZQn4PzYpoQTw",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "64",
                    "parent": "58",
                    "text": "• Cariotipo convencional (valor limitado si se hace FISH)",
                    "guid": "du0uMS7Wjjhi2bcxFgceQA",
                    "children": []
                  },
                  {
                    "id": "65",
                    "parent": "58",
                    "text": "• Perfil de expresión génica (GEP) (si disponible, valor pronóstico adicional)",
                    "guid": "FO532UK7GzwS7_kJCBwwMA",
                    "children": []
                  }
                ]
              },
              {
                "id": "66",
                "parent": "52",
                "text": "◊ Evaluación\nÓsea:",
                "guid": "c-Z9snHt_3FTzL66NB0g5w",
                "children": [
                  {
                    "id": "67",
                    "parent": "66",
                    "text": "• WB-CT de baja dosis o PET/CT (preferidos)",
                    "guid": "GcaAEiSKqIRG3EAnSm-Afw",
                    "children": []
                  },
                  {
                    "id": "68",
                    "parent": "66",
                    "text": "• RM (útil en SMM sospechado, compresión medular, EMD)",
                    "guid": "awzhjAh18qtx06P8QyZqlg",
                    "children": []
                  },
                  {
                    "id": "69",
                    "parent": "66",
                    "text": "• Radiografía esquelética convencional (menos sensible, usar si otros no disponibles)",
                    "guid": "GG0dQWF4_1oHT-xICTQ9pA",
                    "children": []
                  }
                ]
              },
              {
                "id": "70",
                "parent": "52",
                "text": "◊ Otros Estudios:",
                "guid": "fQY3MFfvcDtrzk3zYAq0lw",
                "children": [
                  {
                    "id": "71",
                    "parent": "70",
                    "text": "• Hemograma completo",
                    "guid": "Fx1c-RYNswRr3QPhDgqLKg",
                    "children": []
                  },
                  {
                    "id": "72",
                    "parent": "70",
                    "text": "• Bioquímica (Calcio, función renal, LDH)",
                    "guid": "RORBPE62uxIkEalqWdK5Fg",
                    "children": []
                  },
                  {
                    "id": "73",
                    "parent": "70",
                    "text": "• Beta-2-Microglobulina sérica",
                    "guid": "EXHWTjcBonRh7ulGBVhUAQ",
                    "children": []
                  },
                  {
                    "id": "74",
                    "parent": "70",
                    "text": "• Albúmina sérica",
                    "guid": "KO-h5TW7qAA5dXToQrYh9w",
                    "children": []
                  },
                  {
                    "id": "75",
                    "parent": "70",
                    "text": "• Frotis de sangre periférica (≥5% células plasmáticas = Leucemia de Células Plasmáticas)",
                    "guid": "WkZQhABRtQ8NJaJ3RVMyEA",
                    "children": []
                  },
                  {
                    "id": "76",
                    "parent": "70",
                    "text": "• Serum CrossLaps (CTX) (evaluar recambio óseo)",
                    "guid": "CMenun75RnMIeZynITTE_A",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "77",
            "parent": "38",
            "text": "› Monitorización\ny Respuesta",
            "guid": "YHJFzQ_JiO8qaQKgXXh8_Q",
            "children": [
              {
                "id": "78",
                "parent": "77",
                "text": "◊ Proteína M medible: ≥1 g/dL sérico o ≥200 mg/día urinario",
                "guid": "Z7j5KhY3UJM9gzGUftZWIw",
                "children": []
              },
              {
                "id": "79",
                "parent": "77",
                "text": "◊ Seguimiento: SPEP y FLC sérico mensual (en terapia), cada 3-4 meses (sin terapia)",
                "guid": "LEUDlylgNXUM4OFOcSlE0w",
                "children": []
              },
              {
                "id": "80",
                "parent": "77",
                "text": "◊ Electroforesis de proteínas en orina: Cada 3-6 meses",
                "guid": "eBbwhzDyirhK-_3pCYjG1g",
                "children": []
              },
              {
                "id": "81",
                "parent": "77",
                "text": "◊ Criterios de respuesta **IMWG** revisados y evaluación de Enfermedad Mínima Residual (MRD)",
                "guid": "Z_QtLCzq5zAO4RrXEOPPEQ",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "82",
        "parent": "0",
        "text": "- Clasificación Molecular y\nEstratificación de Riesgo",
        "guid": "",
        "children": [
          {
            "id": "83",
            "parent": "82",
            "text": "› ★ Clasificación\nMolecular Primaria:",
            "guid": "YqaPMEhWj79TmfEJPOzftQ",
            "children": [
              {
                "id": "84",
                "parent": "83",
                "text": "◊ Mieloma Hiperdiploide\n(~45%):",
                "guid": "SKhEzmC_k4ACQBHFUW_siQ",
                "children": [
                  {
                    "id": "85",
                    "parent": "84",
                    "text": "• Trisomías recurrentes (cromosomas impares excepto 1, 13, 21)",
                    "guid": "X7jZ8wq5rmxypLGFQCsfwQ",
                    "children": []
                  },
                  {
                    "id": "86",
                    "parent": "84",
                    "text": "• Generalmente buen pronóstico (riesgo estándar)",
                    "guid": "GoM3Wx0NtCUdo5y-Ajwwhg",
                    "children": []
                  }
                ]
              },
              {
                "id": "87",
                "parent": "83",
                "text": "◊ Mieloma con\nTranslocación IgH\n(~40%):",
                "guid": "M0UEuFsmzlMBEoapX4oITw",
                "children": [
                  {
                    "id": "88",
                    "parent": "87",
                    "text": "• Implica locus IgH en 14q32",
                    "guid": "BIcDyA3zZ_dQs00ifJ30UA",
                    "children": []
                  },
                  {
                    "id": "89",
                    "parent": "87",
                    "text": "• **t(11:14)** (CCND1): ~20% (riesgo estándar)",
                    "guid": "PuXysBuvSwwGJrsmJtof3A",
                    "children": []
                  },
                  {
                    "id": "90",
                    "parent": "87",
                    "text": "• **t(6:14)** (CCND3): ~5% (riesgo estándar)",
                    "guid": "SJoyPBUH1f03ve7uK0DBbA",
                    "children": []
                  },
                  {
                    "id": "91",
                    "parent": "87",
                    "text": "• **t(4:14)** (NSD2): ~10% (riesgo intermedio/alto)",
                    "guid": "XV5lvAtX3_doLaEhJgaqig",
                    "children": []
                  },
                  {
                    "id": "92",
                    "parent": "87",
                    "text": "• **t(14:16)** (c-MAF): ~4% (riesgo intermedio/alto)",
                    "guid": "bBdzd2ptsud3dpcTS9BNag",
                    "children": []
                  },
                  {
                    "id": "93",
                    "parent": "87",
                    "text": "• **t(14:20)** (MAFB): <1% (riesgo intermedio/alto)",
                    "guid": "dSdhU2obSJgL-20rD6qYrw",
                    "children": []
                  }
                ]
              },
              {
                "id": "94",
                "parent": "83",
                "text": "◊ Combinación trisomías + translocación IgH (pequeña proporción)",
                "guid": "Byj8vSmfCeoR5sk1Om4BdQ",
                "children": []
              },
              {
                "id": "95",
                "parent": "83",
                "text": "◊ Ocurren en etapa de MGUS (anomalías primarias)",
                "guid": "BMXYPRL5T94Z-AnECUzcBQ",
                "children": []
              }
            ]
          },
          {
            "id": "96",
            "parent": "82",
            "text": "› ★ Anomalías\nCitogenéticas\nSecundarias:",
            "guid": "IOy31mqrVucF6tBVX9Kqhg",
            "children": [
              {
                "id": "97",
                "parent": "96",
                "text": "◊ Surgen durante el curso de la enfermedad",
                "guid": "Blqh8wwRi3sGrMpiTvTULw",
                "children": []
              },
              {
                "id": "98",
                "parent": "96",
                "text": "◊ **gain(1q)**",
                "guid": "IRlheD5quVB6NZWbfnfHNA",
                "children": []
              },
              {
                "id": "99",
                "parent": "96",
                "text": "◊ **del(1p)**",
                "guid": "ScKZR2JjNr0kfnG_NdoMvg",
                "children": []
              },
              {
                "id": "100",
                "parent": "96",
                "text": "◊ **del(17p)** (implica **TP53**)",
                "guid": "TNDppBv1CNIBqlopQfhK9w",
                "children": []
              },
              {
                "id": "101",
                "parent": "96",
                "text": "◊ del(13)",
                "guid": "BhBRaw2lx1RRouOmDTlOKA",
                "children": []
              },
              {
                "id": "102",
                "parent": "96",
                "text": "◊ Translocaciones secundarias (ej. MYC)",
                "guid": "N0TRPmOJrNtHp0-ePAqpew",
                "children": []
              },
              {
                "id": "103",
                "parent": "96",
                "text": "◊ Influencian curso, respuesta, pronóstico",
                "guid": "doL8umGfWWJFV4WBF2-0kA",
                "children": []
              }
            ]
          },
          {
            "id": "104",
            "parent": "82",
            "text": "› Pronóstico y\nEstratificación de\nRiesgo",
            "guid": "TEqwSUtCVdZ3Ql8WUqVSPA",
            "children": [
              {
                "id": "105",
                "parent": "104",
                "text": "◊ Supervivencia global\n(OS) estimada:",
                "guid": "N1iEkD2g4vgM_CdfPWjV-w",
                "children": [
                  {
                    "id": "106",
                    "parent": "105",
                    "text": "• >10 años en elegibles para trasplante (datos mundo real)",
                    "guid": "V1PhUn3vKXghmiZreG1Cyg",
                    "children": []
                  },
                  {
                    "id": "107",
                    "parent": "105",
                    "text": "• ~5 años en >75 años",
                    "guid": "PFniyRvPvAd25Qn_Bhx8EA",
                    "children": []
                  },
                  {
                    "id": "108",
                    "parent": "105",
                    "text": "• Estimaciones probablemente subestiman supervivencia actual",
                    "guid": "fjLyxBtje7479ojPSwPcaA",
                    "children": []
                  }
                ]
              },
              {
                "id": "109",
                "parent": "104",
                "text": "◊ Factores que afectan OS: Características del huésped, carga tumoral (estadio),\nbiología (citogenética), respuesta a terapia",
                "guid": "S0aqTF6fCwZKoiQkAot7iw",
                "children": []
              },
              {
                "id": "110",
                "parent": "104",
                "text": "◊ Sistemas de\nEstadificación:",
                "guid": "RUzxujRy9hYe8SR6AabUgw",
                "children": [
                  {
                    "id": "111",
                    "parent": "110",
                    "text": "• Durie-Salmon Staging (DSS) (**1975**)",
                    "guid": "Qii34RJJc8I-liUGOKu0mw",
                    "children": []
                  },
                  {
                    "id": "112",
                    "parent": "110",
                    "text": "• International Staging System (ISS) (**2005**)",
                    "guid": "c-jNJAPtqodQG2krQDN9bg",
                    "children": []
                  },
                  {
                    "id": "113",
                    "parent": "110",
                    "text": "• Basado en Beta-2-microglobulina y albúmina sérica",
                    "guid": "TzAAXkddyEES2M-qJoPhsA",
                    "children": []
                  }
                ]
              },
              {
                "id": "114",
                "parent": "104",
                "text": "◊ ★ Revised International Staging System\n(R-ISS) (**2015** - **Palumbo et al.**):",
                "guid": "AuacqQ3DBzh_6SArds9pzg",
                "children": [
                  {
                    "id": "115",
                    "parent": "114",
                    "text": "• Combina ISS + biología (anomalías citogenéticas de alto riesgo y LDH)",
                    "guid": "UEKyHRXWLnkHw1CTTnWk4Q",
                    "children": []
                  },
                  {
                    "id": "116",
                    "parent": "114",
                    "text": "• Estadio I: ISS I, sin citogenética alto riesgo, LDH normal",
                    "guid": "MTmqN0O52WIZeYFJaJIuyA",
                    "children": []
                  },
                  {
                    "id": "117",
                    "parent": "114",
                    "text": "• Estadio II: No I ni III",
                    "guid": "AVq8WiZ1qKgl-wTDTKFmpw",
                    "children": []
                  },
                  {
                    "id": "118",
                    "parent": "114",
                    "text": "• Estadio III: ISS III Y (Citogenética alto riesgo [**t(4:14), t(14;16), del(17p)**] O LDH elevada)",
                    "guid": "BRSzrnCdKOdPLOIyRz1rkA",
                    "children": []
                  }
                ]
              },
              {
                "id": "119",
                "parent": "104",
                "text": "◊ ★ Estratificación de Riesgo\nMayo Clinic (**mSMART**):",
                "guid": "dQr-LEudo200BJ4cMTbk7g",
                "children": [
                  {
                    "id": "120",
                    "parent": "119",
                    "text": "• Riesgo Estándar (~60%): Trisomías, **t(11;14)**, **t(6:14)**",
                    "guid": "EbCxwFAEiVc3Auc8YOCyHg",
                    "children": []
                  },
                  {
                    "id": "121",
                    "parent": "119",
                    "text": "• Alto Riesgo (~40%):",
                    "guid": "F2JRmEnbtuYHZJPOXK9DUg",
                    "children": [
                      {
                        "id": "122",
                        "parent": "121",
                        "text": "◊ **t(4:14)**",
                        "guid": "fk6s_CZVuEheVhfVTpFfGQ",
                        "children": []
                      },
                      {
                        "id": "123",
                        "parent": "121",
                        "text": "◊ **t(14:16)**",
                        "guid": "PCvmwmYZaGkdBwP6bWWQ-Q",
                        "children": []
                      },
                      {
                        "id": "124",
                        "parent": "121",
                        "text": "◊ **t(14;20)**",
                        "guid": "KdNByzaAhUNV97_BKy3-Jg",
                        "children": []
                      },
                      {
                        "id": "125",
                        "parent": "121",
                        "text": "◊ **del(17p)** / **mutación p53**",
                        "guid": "XPYt7HvyxIV3z2TNYgrhmg",
                        "children": []
                      },
                      {
                        "id": "126",
                        "parent": "121",
                        "text": "◊ **gain(1q)**",
                        "guid": "bI_tbEb8Rv8pSE0qb3aKFg",
                        "children": []
                      },
                      {
                        "id": "127",
                        "parent": "121",
                        "text": "◊ **del(1p)**",
                        "guid": "VL9ONykxbVZmRfPkZm__9w",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "128",
                    "parent": "119",
                    "text": "• Doble-Hit: ≥2 factores alto riesgo",
                    "guid": "eTX2rR1I2yBHULIVEJhIRQ",
                    "children": []
                  },
                  {
                    "id": "129",
                    "parent": "119",
                    "text": "• Triple-Hit: ≥3 factores alto riesgo",
                    "guid": "ZySSBk61ReNtR4uYZXM_Aw",
                    "children": []
                  }
                ]
              },
              {
                "id": "130",
                "parent": "104",
                "text": "◊ Otros marcadores de biología agresiva: LDH elevada, células plasmáticas circulantes\n(Leucemia Células Plasmáticas)",
                "guid": "MbcL1lELohcenHXnW4pNog",
                "children": []
              },
              {
                "id": "131",
                "parent": "104",
                "text": "◊ Impacto del tratamiento en\npronóstico de alto riesgo:",
                "guid": "RYP3lG_VhAtMjXGwGkNFyw",
                "children": [
                  {
                    "id": "132",
                    "parent": "131",
                    "text": "• Con **bortezomib** y **ASCT** temprano, OS mediana con **del(17p)** ~8 años\n(similar a riesgo estándar)",
                    "guid": "B4wnWnSUNakGuEvIZIJVRg",
                    "children": []
                  },
                  {
                    "id": "133",
                    "parent": "131",
                    "text": "• OS menor con **t(4:14)** y **gain(1q)** en el mismo ensayo",
                    "guid": "cIb6Ln6HsJVGjTbhXRbnmg",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "id": "134",
        "parent": "0",
        "text": "- Tratamiento del Mieloma Recién Diagnosticado (Sintomático)",
        "guid": "VXwwAQIBoGU_uBf8PgyifA",
        "children": [
          {
            "id": "135",
            "parent": "134",
            "text": "› ★ Principios Generales",
            "guid": "GQbxYTLTZZQAs0XDEjzoDg",
            "children": [
              {
                "id": "136",
                "parent": "135",
                "text": "◊ Evolución rápida del tratamiento",
                "guid": "UBxAtEgD99gi1TBUN0DSuw",
                "children": []
              },
              {
                "id": "137",
                "parent": "135",
                "text": "◊ Agentes clave iniciales: **talidomida**, **bortezomib**, **lenalidomida**",
                "guid": "Frk9vBAcu-wctBG-C8Q76A",
                "children": []
              },
              {
                "id": "138",
                "parent": "135",
                "text": "◊ Agentes más nuevos (última década): **carfilzomib**, **pomalidomida**, **ixazomib**,\n**elotuzumab**, **daratumumab**, **isatuximab**, **selinexor**, **belantamab mafodotin**,\n**teclistamab**, **talquetamab**, **elranatamab**, terapias **CAR-T**",
                "guid": "W7pfWVC4r9o8-yDWDXFrMA",
                "children": []
              },
              {
                "id": "139",
                "parent": "135",
                "text": "◊ Combinaciones comunes (Ver Tabla 6 del documento original)",
                "guid": "IcRR8VuXlr1o-7jSKVB5TA",
                "children": []
              },
              {
                "id": "140",
                "parent": "135",
                "text": "◊ Mecanismos\nde Acción:",
                "guid": "HSqFdE62OFFveWLvbUbGKA",
                "children": [
                  {
                    "id": "141",
                    "parent": "140",
                    "text": "• ★ IMiDs (**talidomida, lenalidomida, pomalidomida**): Se unen a cereblon\n→ degradación de **IKZF1** (Ikaros) y **IKZF3** (Aiolos)",
                    "guid": "UCvMZm-0BJoN0s6SQLLGlA",
                    "children": []
                  },
                  {
                    "id": "142",
                    "parent": "140",
                    "text": "• ★ Inhibidores del Proteasoma (**bortezomib, carfilzomib, ixazomib**)",
                    "guid": "bju1L1RgBXMdya4vM7-sww",
                    "children": []
                  },
                  {
                    "id": "143",
                    "parent": "140",
                    "text": "• ★ Anticuerpos Monoclonales:",
                    "guid": "RDWJf2pXH99OAvKOXTx64A",
                    "children": [
                      {
                        "id": "144",
                        "parent": "143",
                        "text": "◊ **Elotuzumab** (anti-SLAMF7)",
                        "guid": "FrowKhJOk0Mkh5jjLXNt5g",
                        "children": []
                      },
                      {
                        "id": "145",
                        "parent": "143",
                        "text": "◊ **Daratumumab**, **Isatuximab** (anti-CD38)",
                        "guid": "ImtPL0E7qqE5N6nOfiWuiA",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "146",
                    "parent": "140",
                    "text": "• ★ Conjugado Anticuerpo-Fármaco: **Belantamab mafodotin** (anti-BCMA + monometil auristatina-F)",
                    "guid": "EfRafHYyyqQLlxm4M7isbQ",
                    "children": []
                  },
                  {
                    "id": "147",
                    "parent": "140",
                    "text": "• ★ Terapias **CAR-T**: **Idecabtagene vicleucel (ide-cel)**, **Ciltacabtagene autoleucel (cilta-cel)** (anti-BCMA)",
                    "guid": "UcphYXSS0opdCSW5IfYtyA",
                    "children": []
                  },
                  {
                    "id": "148",
                    "parent": "140",
                    "text": "• ★ Anticuerpos\nBiespecíficos:",
                    "guid": "YnX0URnCputnKQIGBOFDgA",
                    "children": [
                      {
                        "id": "149",
                        "parent": "148",
                        "text": "◊ **Teclistamab**, **Elranatamab** (BCMA x CD3)",
                        "guid": "ZEbXJGrb9ExiqPRcUoKMUw",
                        "children": []
                      },
                      {
                        "id": "150",
                        "parent": "148",
                        "text": "◊ **Talquetamab** (GPRC5D x CD3)",
                        "guid": "Pzv5vwByoosGQjkWA3GDPg",
                        "children": []
                      },
                      {
                        "id": "151",
                        "parent": "148",
                        "text": "◊ Enfoque tratamiento basado en elegibilidad para ASCT y riesgo (Ver Figura 1 del documento original)",
                        "guid": "asnCa1RFK6Vgrf4fB_RH3w",
                        "children": []
                      },
                      {
                        "id": "152",
                        "parent": "148",
                        "text": "◊ Debate \"cura vs control\"",
                        "guid": "Ivtj9lAnYQ51Ow4HObWUIA",
                        "children": []
                      },
                      {
                        "id": "153",
                        "parent": "148",
                        "text": "◊ Importancia de MRD negativa (valor pronóstico, posible subrogado)",
                        "guid": "Wv5RjCBgq9QDBvIIbPKsCA",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "id": "154",
            "parent": "134",
            "text": "› Pacientes Elegibles para ASCT\n(Figura 1A del documento original)",
            "guid": "FpN2eA6eC8Egq1h2aF3X2g",
            "children": [
              {
                "id": "155",
                "parent": "154",
                "text": "◊ Terapia de Inducción (3-4 ciclos\nantes de colecta):",
                "guid": "AzDeS320fi8KVAWiZ3e1cA",
                "children": [
                  {
                    "id": "156",
                    "parent": "155",
                    "text": "• ★ Régimen Preferido (Cuádruple): **Dara-VRd** (**Daratumumab** + **Bortezomib** + **Lenalidomida** + **Dexametasona**)\no **Isa-VRd** (**Isatuximab** + **VRd**)",
                    "guid": "aJBye2z8-f45-kHDJ8xsOw",
                    "children": []
                  }
                ]
              },
              {
                "id": "157",
                "parent": "154",
                "text": "◊ Superioridad demostrada vs **VRd**\n(tasas respuesta, MRD neg, PFS)",
                "guid": "bW-cikA8etorPe95WDle9Q",
                "children": [
                  {
                    "id": "158",
                    "parent": "157",
                    "text": "• Alternativa (Triple): **VRd** o **DRd** (si cuádruples no disponibles)",
                    "guid": "FIGmfwvr7ZhgLabUN30KdQ",
                    "children": []
                  },
                  {
                    "id": "159",
                    "parent": "157",
                    "text": "• Alternativa (Neuropatía preexistente): **Dara-KRd**",
                    "guid": "XBNOplVotNtxMp6WPolC9w",
                    "children": []
                  },
                  {
                    "id": "160",
                    "parent": "157",
                    "text": "• Alternativa (Insuficiencia renal aguda / sospecha nefropatía por cadenas ligeras):\n**Daratumumab** + **VCd** (+/- plasmaféresis)",
                    "guid": "bytbxlhboJxDaoZ3SimtUw",
                    "children": []
                  },
                  {
                    "id": "161",
                    "parent": "157",
                    "text": "• Alternativa (Enfermedad agresiva: Leucemia Células Plasmáticas, Plasmocitomas extramedulares múltiples):\n**VDT-PACE** o **PAD** + **Daratumumab**",
                    "guid": "eLxMcUZxeIA3HFlbD0_C6Q",
                    "children": []
                  }
                ]
              },
              {
                "id": "162",
                "parent": "154",
                "text": "◊ Colecta de\nCélulas Madre:",
                "guid": "aj3xkncgJCQ3n31nWWlNWQ",
                "children": [
                  {
                    "id": "163",
                    "parent": "162",
                    "text": "• Puede requerir plerixafor si >4-6 ciclos de **lenalidomida**",
                    "guid": "Oe7UmhEW_jE0p5XjTnB7GQ",
                    "children": []
                  },
                  {
                    "id": "164",
                    "parent": "162",
                    "text": "• **Bortezomib** no afecta movilización",
                    "guid": "HQLryRTVPLcF7YWOeRY6cA",
                    "children": []
                  }
                ]
              },
              {
                "id": "165",
                "parent": "154",
                "text": "◊ Estrategia\nPost-Inducción:",
                "guid": "KApAzxzeeF1duQm-WoFGqA",
                "children": [
                  {
                    "id": "166",
                    "parent": "165",
                    "text": "• ★ Riesgo Estándar:",
                    "guid": "T3vEwXsKA98jkvqsSDgRMg",
                    "children": [
                      {
                        "id": "167",
                        "parent": "166",
                        "text": "◊ Opción 1: ASCT temprano → Mantenimiento con **Lenalidomida**",
                        "guid": "QXt8X1qvVAdXh9QbFosAoA",
                        "children": []
                      },
                      {
                        "id": "168",
                        "parent": "166",
                        "text": "◊ Opción 2: Criopreservar células → Continuar inducción (total 8-12 ciclos)\n→ Mantenimiento con **Lenalidomida** (ASCT al primer relapso)",
                        "guid": "MncF2U81bt9uy2MsB_M12g",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "169",
                    "parent": "165",
                    "text": "• ★ Alto Riesgo\n(especialmente\nDoble/Triple-Hit):",
                    "guid": "UTcPRC6DeylF_9hWQDWpqA",
                    "children": [
                      {
                        "id": "170",
                        "parent": "169",
                        "text": "◊ ASCT temprano → Mantenimiento con **Bortezomib** + **Lenalidomida**",
                        "guid": "KDXU6SvY5w4co-CWYiSpgw",
                        "children": []
                      },
                      {
                        "id": "171",
                        "parent": "169",
                        "text": "◊ Consideraciones\nTerapéuticas:",
                        "guid": "PO_lP1FLdnkwlSScWfLRCA",
                        "children": [
                          {
                            "id": "172",
                            "parent": "171",
                            "text": "• Preferir **dexametasona** a dosis bajas (40 mg semanal)",
                            "guid": "ZiCzMDaCqipTCQt4UF6kww",
                            "children": []
                          },
                          {
                            "id": "173",
                            "parent": "171",
                            "text": "• **Bortezomib** subcutáneo semanal para reducir neurotoxicidad",
                            "guid": "LaLOTwqoiOApx_IcfR6TEA",
                            "children": []
                          },
                          {
                            "id": "174",
                            "parent": "171",
                            "text": "• Profilaxis antitrombótica con **lenalidomida** (Aspirina o anticoagulación según riesgo)",
                            "guid": "BbKMv01a7MhFVqRCRy4JHg",
                            "children": []
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "id": "175",
            "parent": "134",
            "text": "› Pacientes No Elegibles para ASCT\n(Figura 1B del documento original)",
            "guid": "FAQ0HmKxifg_SoD2DXTnYw",
            "children": [
              {
                "id": "176",
                "parent": "175",
                "text": "◊ Definición (EEUU vs Europa):\nNo por edad estricta en EEUU",
                "guid": "bBPnPEyEbOpidHyCPUr2gQ",
                "children": [
                  {
                    "id": "177",
                    "parent": "176",
                    "text": "◊ ★ Factor clave: Fragilidad (Frail) vs No Fragilidad (Not Frail)",
                    "guid": "ewfoEyh0VNl9gKApIz28_A",
                    "children": []
                  },
                  {
                    "id": "178",
                    "parent": "176",
                    "text": "◊ ★ Riesgo Estándar:",
                    "guid": "VE075xokgMAFYmZ_ET0hJg",
                    "children": [
                      {
                        "id": "179",
                        "parent": "178",
                        "text": "• Frágil: **VRd** (8-12 ciclos) → Mantenimiento **Lenalidomida**, O **DRd** continuo",
                        "guid": "a2_3OTX3ixtrL_IuUZCqag",
                        "children": []
                      },
                      {
                        "id": "180",
                        "parent": "178",
                        "text": "• No Frágil: **Dara-VRd** o **Isa-VRd** (8-12 ciclos) → Mantenimiento **Lenalidomida**",
                        "guid": "bHo1Rj44_ach708tGh0DlQ",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "181",
                    "parent": "176",
                    "text": "◊ ★ Alto Riesgo:",
                    "guid": "SOGGh0u3QUkXO5alTpQTRg",
                    "children": [
                      {
                        "id": "182",
                        "parent": "181",
                        "text": "• Frágil: **VRd** (8-12 ciclos) → Mantenimiento **Bortezomib** + **Lenalidomida**",
                        "guid": "GRIuEVySOucVwhxkQRxu4A",
                        "children": []
                      },
                      {
                        "id": "183",
                        "parent": "181",
                        "text": "• No Frágil: **Dara-VRd** o **Isa-VRd** (8-12 ciclos) → Mantenimiento **Bortezomib** + **Lenalidomida**",
                        "guid": "eXCzRHN7JiIbnbWJZYSagQ",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "id": "184",
                "parent": "175",
                "text": "◊ Consideraciones\nTerapéuticas:",
                "guid": "P_-TDH4SMgsiz5ECOwd7IA",
                "children": [
                  {
                    "id": "185",
                    "parent": "184",
                    "text": "• **DRd** requiere 3 drogas hasta progresión (más caro a largo plazo vs **VRd** limitado)",
                    "guid": "JoaG5CBQMSteRTgcetPCyw",
                    "children": []
                  },
                  {
                    "id": "186",
                    "parent": "184",
                    "text": "• **Ixazomib** (oral) como alternativa a **bortezomib** si hay problemas logísticos (**IRd**)",
                    "guid": "OnSx62OnnpwMEOPxJeSpJQ",
                    "children": []
                  },
                  {
                    "id": "187",
                    "parent": "184",
                    "text": "• En ancianos frágiles: Dosis reducidas de **lenalidomida**, **dexametasona** 20 mg semanal (reducir/suspender después)",
                    "guid": "GZ8pt3dA1iB3dVOPBhle_Q",
                    "children": []
                  },
                  {
                    "id": "188",
                    "parent": "184",
                    "text": "• Regímenes basados en Melfalán no recomendados",
                    "guid": "NXnTxxlkorwgNmKSfltaTg",
                    "children": []
                  },
                  {
                    "id": "189",
                    "parent": "184",
                    "text": "• **VCd** como alternativa si acceso limitado a otros agentes",
                    "guid": "ZRvkBTdx-TdM722Ufi4SFg",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "190",
            "parent": "134",
            "text": "› Trasplante de Células Madre\nHematopoyéticas (ASCT)",
            "guid": "B-D-hUSHizoqeIsXPJ4oTg",
            "children": [
              {
                "id": "191",
                "parent": "190",
                "text": "◊ ★ ASCT Autólogo:",
                "guid": "ViywGlroNn9y-YHkFixDJg",
                "children": [
                  {
                    "id": "192",
                    "parent": "191",
                    "text": "• Mejora OS mediana en ~12 meses",
                    "guid": "WPpoixXJEuZRM75Gf4Dvbw",
                    "children": []
                  },
                  {
                    "id": "193",
                    "parent": "191",
                    "text": "• ★ ASCT Temprano vs Tardío (al relapso): PFS mejor con temprano, pero OS similar en ensayos **IFM 2009** y **DETERMINATION**",
                    "guid": "NhlEES949mN6VLI7cI31_Q",
                    "children": []
                  }
                ]
              },
              {
                "id": "194",
                "parent": "190",
                "text": "◊ Retrasar ASCT es razonable en Riesgo Estándar (con criopreservación temprana)",
                "guid": "EyCU_wZlliwWcp8iLL--tg",
                "children": [
                  {
                    "id": "195",
                    "parent": "194",
                    "text": "• ASCT Tándem (Doble): Rol incierto, datos contradictorios",
                    "guid": "faZsTA3n8rEy2R20MyBAEw",
                    "children": []
                  }
                ]
              },
              {
                "id": "196",
                "parent": "190",
                "text": "◊ No recomendado de rutina fuera de ensayos clínicos",
                "guid": "J0yVbVMPgEYxe5phDGh5cg",
                "children": []
              },
              {
                "id": "197",
                "parent": "190",
                "text": "◊ Considerar en alto riesgo sin RC post-primer ASCT",
                "guid": "CoF5fn5rB_UKlouIHoWtnA",
                "children": []
              },
              {
                "id": "198",
                "parent": "190",
                "text": "◊ Consolidación\nPost-ASCT:",
                "guid": "YRyR7UnhDH4r-pT_N0lCBw",
                "children": [
                  {
                    "id": "199",
                    "parent": "198",
                    "text": "• Corto curso de terapia (≥2 drogas) antes de mantenimiento",
                    "guid": "JMlC_h70FuNNdYUufcOriQ",
                    "children": []
                  },
                  {
                    "id": "200",
                    "parent": "198",
                    "text": "• Ensayo **BMT-CTN 0702**: Consolidación con **VRd** no mostró beneficio significativo vs mantenimiento solo",
                    "guid": "NL0pyR6pQ3R9RJr4atZt2w",
                    "children": []
                  },
                  {
                    "id": "201",
                    "parent": "198",
                    "text": "• Generalmente no recomendada fuera de ensayos clínicos",
                    "guid": "TiI513eZTTNbZGPYYULO1g",
                    "children": []
                  }
                ]
              },
              {
                "id": "202",
                "parent": "190",
                "text": "◊ Trasplante\nAlogénico:",
                "guid": "ff7jYHHXAvoOAo2Ne6VPrA",
                "children": [
                  {
                    "id": "203",
                    "parent": "202",
                    "text": "• Rol controversial, resultados conflictivos",
                    "guid": "f771q0Dbq0EuxY_AJwuLGA",
                    "children": []
                  },
                  {
                    "id": "204",
                    "parent": "202",
                    "text": "• Mortalidad relacionada al tratamiento (TRM) alta (10-20%), tasas GVHD altas",
                    "guid": "E-srh2BBKiEzdASKHmylBQ",
                    "children": []
                  },
                  {
                    "id": "205",
                    "parent": "202",
                    "text": "• Considerado investigacional",
                    "guid": "XqwyFz4KkBI88lKiP8jEBA",
                    "children": []
                  },
                  {
                    "id": "206",
                    "parent": "202",
                    "text": "• Posible opción para jóvenes con alto riesgo en recaída, aceptando riesgos",
                    "guid": "B-uckGjs56F3EgYMLLTfjg",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "207",
            "parent": "134",
            "text": "› ★ Terapia de Mantenimiento",
            "guid": "ScH7DWl1r9gRlsGbKzYLOA",
            "children": [
              {
                "id": "208",
                "parent": "207",
                "text": "◊ Indicada post-ASCT o post 8-12 ciclos de inducción sin ASCT",
                "guid": "YzDOrie9JhAndJYpMVMIhg",
                "children": []
              },
              {
                "id": "209",
                "parent": "207",
                "text": "◊ ★ Riesgo Estándar: **Lenalidomida**\n(Estándar de cuidado)",
                "guid": "H1ZzQwLY-gESlddcHVVWow",
                "children": [
                  {
                    "id": "210",
                    "parent": "209",
                    "text": "• Mejora PFS y OS (Meta-análisis)",
                    "guid": "dK_8-yCYZOkY-qZQdG7ypg",
                    "children": []
                  },
                  {
                    "id": "211",
                    "parent": "209",
                    "text": "• Riesgo aumentado (2-3x) de segundos cánceres",
                    "guid": "YXQQKkfANhAben2-dV87sg",
                    "children": []
                  }
                ]
              },
              {
                "id": "212",
                "parent": "207",
                "text": "◊ ★ Alto Riesgo: **Bortezomib**\n(+ **Lenalidomida**)",
                "guid": "KAFgMU7ugkgTy-C3Bq2SSA",
                "children": [
                  {
                    "id": "213",
                    "parent": "212",
                    "text": "• Beneficio OS con **Bortezomib** (cada 2 sem), especialmente **del(17p)**",
                    "guid": "DPkSWlC-M1lGdlZNFOSu6w",
                    "children": []
                  },
                  {
                    "id": "214",
                    "parent": "212",
                    "text": "• Impacto de **Lenalidomida** sola es incierto (Meta-análisis no mostró beneficio OS claro)",
                    "guid": "Oasa-z2IXFlBmY55QYwZgA",
                    "children": []
                  },
                  {
                    "id": "215",
                    "parent": "212",
                    "text": "• **Ixazomib** como alternativa oral a **bortezomib**",
                    "guid": "Ag_nk2wSGZF-KkHOZUC2QQ",
                    "children": []
                  }
                ]
              },
              {
                "id": "216",
                "parent": "207",
                "text": "◊ Duración Óptima: Desconocida, en investigación (ej.\nEnsayo ECOG NCT03941860: progresión vs 2 años)",
                "guid": "E88_oSWe1_gWk77HMyWy5A",
                "children": []
              },
              {
                "id": "217",
                "parent": "207",
                "text": "◊ Rol de **Daratumumab** en Mantenimiento: Incierto si añade beneficio\nsignificativo a **Lenalidomida**; no recomendado de rutina hasta más datos",
                "guid": "KHfR-SkpliRQewmIHSfO9Q",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "218",
        "parent": "0",
        "text": "- Tratamiento del Mieloma\nMúltiple Recaído/Refractario",
        "guid": "",
        "children": [
          {
            "id": "219",
            "parent": "218",
            "text": "› Principios\nGenerales",
            "guid": "MTXl6C0RP1oglUbqWTdGGQ",
            "children": [
              {
                "id": "220",
                "parent": "219",
                "text": "◊ Casi todos los pacientes recaen eventualmente",
                "guid": "e__BojRhJ6Ff5NhiCPjT_Q",
                "children": []
              },
              {
                "id": "221",
                "parent": "219",
                "text": "◊ Duración de remisión disminuye con cada línea",
                "guid": "BR9a-yZbLq8d3YLoPsp19g",
                "children": []
              },
              {
                "id": "222",
                "parent": "219",
                "text": "◊ Pronóstico pobre si refractario a **lenalidomida** y **bortezomib** (PFS ~5m, OS ~9m)",
                "guid": "Y-OLCF93EWEAVo92ZfNymw",
                "children": []
              },
              {
                "id": "223",
                "parent": "219",
                "text": "◊ Elección de régimen compleja: Factores TRAP (Timing, Response, Aggressiveness, Performance status)",
                "guid": "S4kq8n6A0URLNCjcX1hqkw",
                "children": []
              },
              {
                "id": "224",
                "parent": "219",
                "text": "◊ ★ Considerar\nASCT de rescate:",
                "guid": "JB-pPGHH56QSfh14TJd7Ng",
                "children": [
                  {
                    "id": "225",
                    "parent": "224",
                    "text": "• Si nunca tuvo uno antes y es elegible",
                    "guid": "CvF9yGL5JwBpv0orVLN41Q",
                    "children": []
                  },
                  {
                    "id": "226",
                    "parent": "224",
                    "text": "• Si tuvo remisión >36 meses con mantenimiento post-primer ASCT",
                    "guid": "TG7W2HtWC8Z_6YQNfaS8wA",
                    "children": []
                  }
                ]
              },
              {
                "id": "227",
                "parent": "219",
                "text": "◊ Generalmente se necesita régimen triplete con\n≥2 drogas nuevas a las que no sea refractario",
                "guid": "KGdLICB-yvdW3ALZJGcMww",
                "children": []
              },
              {
                "id": "228",
                "parent": "219",
                "text": "◊ Enfoque sugerido (Ver Figura 2 del documento original)",
                "guid": "VN_ymTbA2zstX-DAWf9NlA",
                "children": []
              }
            ]
          },
          {
            "id": "229",
            "parent": "218",
            "text": "› Opciones Terapéuticas\n(Ver Tabla 6, 8, 9 del\ndocumento original)",
            "guid": "XRwJ6ks9Y6gYycOKQP-U8g",
            "children": [
              {
                "id": "230",
                "parent": "229",
                "text": "◊ ★ Primera Recaída (Figura 2A\ndel documento original)",
                "guid": "ApeBxkBXVBhz_vd3cAUgbg",
                "children": [
                  {
                    "id": "231",
                    "parent": "230",
                    "text": "• No refractario a\n**Lenalidomida**:",
                    "guid": "U-8YDmgUKAcIWEi3XuCV1g",
                    "children": [
                      {
                        "id": "232",
                        "parent": "231",
                        "text": "◊ No refractario a anti-CD38:\n**DRd** (preferido)",
                        "guid": "KrR1CRkgUwAm8weNdj2f_A",
                        "children": []
                      },
                      {
                        "id": "233",
                        "parent": "231",
                        "text": "◊ Refractario/Recaída en\nanti-CD38: **KRd** (preferido);\n**ERd**, **IRd** (alternativas)",
                        "guid": "F6EkRHInMGpVlgqPO8DNgQ",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "234",
                    "parent": "230",
                    "text": "• Refractario a\n**Lenalidomida**:",
                    "guid": "Ir3AtGeb10wC253df9nKnw",
                    "children": [
                      {
                        "id": "235",
                        "parent": "234",
                        "text": "◊ No refractario a anti-CD38: **DKd**\no **Isa-Kd** (preferido); **DPd** o\n**Isa-Pd** (alternativas)",
                        "guid": "Sw1PB3IXkuIzlA6rF3wl3w",
                        "children": []
                      },
                      {
                        "id": "236",
                        "parent": "234",
                        "text": "◊ Refractario/Recaída en anti-CD38:\n**KPd** o **KCd** (preferido); **VCd**\no **EPd** (alternativas)",
                        "guid": "bW2eqDN9krkVIOKfFdTpyQ",
                        "children": []
                      },
                      {
                        "id": "237",
                        "parent": "234",
                        "text": "◊ ★ Segunda Recaída y Posteriores\n(Figura 2B del documento original)",
                        "guid": "U_xdsGv85Xk6O_aMKNxQSQ",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "238",
                    "parent": "230",
                    "text": "• Considerar opción de primera recaída\ncon ≥2 drogas no refractarias",
                    "guid": "Mtk69BulYWdA2V-RXY2v_Q",
                    "children": []
                  },
                  {
                    "id": "239",
                    "parent": "230",
                    "text": "• ★ Opciones Adicionales:",
                    "guid": "WfOXiSlhWokIJ6YtLeKvlw",
                    "children": [
                      {
                        "id": "240",
                        "parent": "239",
                        "text": "◊ ★ Terapias dirigidas a BCMA:",
                        "guid": "NMW0Z2fMZx9Ty0_5TGbYrA",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "241",
                    "parent": "230",
                    "text": "• ★ **CAR-T**:\n**Ide-cel**, **Cilta-cel**",
                    "guid": "EXWCkBB_7uQMw0VtXILRmA",
                    "children": [
                      {
                        "id": "242",
                        "parent": "241",
                        "text": "› Aprobados tras menos líneas de terapia basados en ensayos KarMMa-3 y CARTITUDE-4",
                        "guid": "c9Tm0Qkf2hcF2go3R9FEgg",
                        "children": []
                      },
                      {
                        "id": "243",
                        "parent": "241",
                        "text": "› CRS y neurotoxicidad son\nefectos adversos clave",
                        "guid": "Dy6UEFiNqnU4GMMBQ_RIeA",
                        "children": [
                          {
                            "id": "244",
                            "parent": "243",
                            "text": "• ★ Anticuerpos Biespecíficos (BCMA x CD3):\n**Teclistamab**, **Elranatamab**",
                            "guid": "dRy_kEAWAMNwrZTLF9qARA",
                            "children": []
                          },
                          {
                            "id": "245",
                            "parent": "243",
                            "text": "• Conjugado Anticuerpo-Fármaco: **Belantamab mafodotin**\n(probable reaprobación tras ensayos DREAMM-7 y -8)",
                            "guid": "J7HYD3OJMqkXtErjWosTAw",
                            "children": []
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "id": "246",
                "parent": "229",
                "text": "◊ ★ Anticuerpo Biespecífico\n(GPRC5D x CD3): **Talquetamab**",
                "guid": "QFoRlAvkEvoQWyEkGk2pHQ",
                "children": [
                  {
                    "id": "247",
                    "parent": "246",
                    "text": "› Útil post-terapia\nanti-BCMA",
                    "guid": "KQK2NVTzniEjPcGsK5o3-w",
                    "children": []
                  },
                  {
                    "id": "248",
                    "parent": "246",
                    "text": "› Efectos adversos únicos:\ndisgeusia, toxicidad\npiel/uñas, pérdida de peso",
                    "guid": "FUryORc8uSMbn1hpCR_ZCw",
                    "children": []
                  }
                ]
              },
              {
                "id": "249",
                "parent": "229",
                "text": "◊ ★ **Selinexor** (Inhibidor\nXPO1) + **Vd** (**SVd**)",
                "guid": "IFyTOiF5YqFQ8R2NFXlSyg",
                "children": [
                  {
                    "id": "250",
                    "parent": "249",
                    "text": "› Toxicidad ocular\n(queratopatía) es limitante",
                    "guid": "NUVtgxiCx1FIMFi0RrrwFA",
                    "children": []
                  }
                ]
              },
              {
                "id": "251",
                "parent": "229",
                "text": "◊ ★ **Venetoclax** (inhibidor BCL2) -\nSOLO para Mieloma **t(11:14)** (uso\noff-label/investigacional)",
                "guid": "YY9jZEGeslgtU9MPCUE7dA",
                "children": []
              },
              {
                "id": "252",
                "parent": "229",
                "text": "◊ Regímenes basados en\nPomalidomida (**DPd**,\n**Isa-Pd**, **EPd**, **KPd**,\n**Pd**)",
                "guid": "NSflAUUIHfJjzE53RFZ5Eg",
                "children": []
              },
              {
                "id": "253",
                "parent": "229",
                "text": "◊ Regímenes basados en\nCarfilzomib (**KRd**, **DKd**,\n**Isa-Kd**, **KPd**, **KCd**)",
                "guid": "HZXIZxvlEXgISsGKXe_Z-w",
                "children": []
              },
              {
                "id": "254",
                "parent": "229",
                "text": "◊ Regímenes basados en\nIxazomib (**IRd**)",
                "guid": "J8kkcxil4q54PYMYXQ6R9g",
                "children": []
              },
              {
                "id": "255",
                "parent": "229",
                "text": "◊ Regímenes basados en\nElotuzumab (**ERd**, **EPd**)",
                "guid": "MSip_0Bt28wjyYIKWitgNA",
                "children": []
              },
              {
                "id": "256",
                "parent": "229",
                "text": "◊ Regímenes basados en\nIsatuximab (**Isa-Pd**, **Isa-Kd**)",
                "guid": "FWF57UcHQ7YFxZgvKqxsJw",
                "children": []
              },
              {
                "id": "257",
                "parent": "229",
                "text": "◊ Regímenes con Alquilantes\n(ej. **VCd**, **KCd**, Melfalán\nIV, Bendamustina)",
                "guid": "XkP82iFk8JgzzEUyfqCQFA",
                "children": []
              },
              {
                "id": "258",
                "parent": "229",
                "text": "◊ Regímenes con Antraciclinas (ej. **PAD**,\n**VDT-PACE**) - Especialmente para\nrecaída agresiva (PCL, EMD)",
                "guid": "Qt5TOQS9Yr8UGeLfJG22ng",
                "children": []
              },
              {
                "id": "259",
                "parent": "229",
                "text": "◊ Trasplante Alogénico (jóvenes,\nalto riesgo, con donante)",
                "guid": "BnXT4BF7QIk_2nMrJAucSA",
                "children": []
              },
              {
                "id": "260",
                "parent": "229",
                "text": "◊ ★ Opciones\nEmergentes/Investigacionales:",
                "guid": "LWBSAkglNLUB-3ZDVSl2dQ",
                "children": [
                  {
                    "id": "261",
                    "parent": "260",
                    "text": "• Nuevos biespecíficos (ej.\nTNB-383B, REGN 5458,\nCevostamab (anti-FcRH5))",
                    "guid": "RlwVF0Ftte4trvISe4P6GQ",
                    "children": []
                  },
                  {
                    "id": "262",
                    "parent": "260",
                    "text": "• Moduladores Cereblon E3\nLigasa (CELMoDs):\n**Iberdomida**,\n**Mezigdomida**",
                    "guid": "YMsXY3o4-VwyOAhrEfPBYg",
                    "children": []
                  }
                ]
              },
              {
                "id": "263",
                "parent": "229",
                "text": "◊ Duración de Terapia en Recaída: No bien definida,\nconsiderar parar inhibidores proteasoma parenterales\ntras alcanzar meseta estable",
                "guid": "OqbVKFYBinZsHyGWUAhPFg",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "id": "264",
        "parent": "0",
        "text": "- Cuidado de Soporte y\nCondiciones Relacionadas",
        "guid": "",
        "children": [
          {
            "id": "265",
            "parent": "264",
            "text": "› ★ Salud Ósea",
            "guid": "HQjOLHHkucV6tLs9e0zLBg",
            "children": [
              {
                "id": "266",
                "parent": "265",
                "text": "◊ Bifosfonatos: **Ácido Zoledrónico** o **Pamidronato**\n(recomendados para todos)",
                "guid": "E0mqXS6BAG957VsbVif9lw",
                "children": [
                  {
                    "id": "267",
                    "parent": "266",
                    "text": "• Considerar dosis menos frecuente\n(cada 3-4 meses)",
                    "guid": "Mz5jLg4HPfp6lbQ1eZp4RQ",
                    "children": []
                  }
                ]
              },
              {
                "id": "268",
                "parent": "265",
                "text": "◊ **Denosumab** (anti-RANKL): Alternativa\n(especialmente con disfunción renal)",
                "guid": "T3Tz6ChEpkd1HnJeVerHyA",
                "children": [
                  {
                    "id": "269",
                    "parent": "268",
                    "text": "• Dar dosis de bifosfonato al discontinuar\npara evitar rebote osteoclástico",
                    "guid": "Ob_m0DT45Yl59mQQZyA40g",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "270",
            "parent": "264",
            "text": "› ★ Prevención de Infecciones\n(Guías **IMWG**)",
            "guid": "fR4aPnvx2lQ8Sa9HXekxoQ",
            "children": [
              {
                "id": "271",
                "parent": "270",
                "text": "◊ Vacunación COVID (respuesta inadecuada, necesitan refuerzos)",
                "guid": "dirTsG6Bt7Nv3PMDMNGo2A",
                "children": []
              },
              {
                "id": "272",
                "parent": "270",
                "text": "◊ Profilaxis antibacteriana (ej. Levofloxacino) primeros 2-3 meses de terapia inicial",
                "guid": "RINCKVv8FJkA2ffuYYwQVQ",
                "children": []
              },
              {
                "id": "273",
                "parent": "270",
                "text": "◊ Profilaxis Pneumocystis jirovecii (ej. Trimetoprim-sulfametoxazol) a largo plazo con esteroides o anti-CD38",
                "guid": "TeDOXnuOsytc2NtcYSp4vA",
                "children": []
              },
              {
                "id": "274",
                "parent": "270",
                "text": "◊ Profilaxis Herpes Zoster (ej. Aciclovir) con inhibidores proteasoma, anti-CD38, elotuzumab",
                "guid": "Kg-zmlbGNnc3UnZTXU4WyA",
                "children": []
              },
              {
                "id": "275",
                "parent": "270",
                "text": "◊ Inmunoglobulina IV (considerar en hipogammaglobulinemia con infecciones respiratorias frecuentes en tto con daratumumab)",
                "guid": "ZM10cTHoKohW6I8ONEJoWQ",
                "children": []
              }
            ]
          },
          {
            "id": "276",
            "parent": "264",
            "text": "› ★ Mieloma Múltiple Asintomático (Smoldering - SMM)",
            "guid": "WizQz0wHAWwKLTAhE-y3nw",
            "children": [
              {
                "id": "277",
                "parent": "276",
                "text": "◊ Estadio entre MGUS y Mieloma sintomático",
                "guid": "AP_m9gQjlDJ7DPByfh4BNA",
                "children": []
              },
              {
                "id": "278",
                "parent": "276",
                "text": "◊ Grupo heterogéneo",
                "guid": "ABVuhjdWn7lcBzLWdkBCNg",
                "children": []
              },
              {
                "id": "279",
                "parent": "276",
                "text": "◊ Riesgo de progresión variable",
                "guid": "JdhXbEvkJdknEesOaluZlQ",
                "children": []
              },
              {
                "id": "280",
                "parent": "276",
                "text": "◊ Reclasificación de ultra-alto riesgo como Mieloma (nuevos criterios **IMWG**)",
                "guid": "J-A6cyfr4v1L56nrdcEI0Q",
                "children": []
              },
              {
                "id": "281",
                "parent": "276",
                "text": "◊ Estratificación de Riesgo SMM\nActual (post-revisión **IMWG**):",
                "guid": "I3qWKCjAhUdW64GNTYpJww",
                "children": [
                  {
                    "id": "282",
                    "parent": "281",
                    "text": "• Bajo Riesgo (~5% progresión/año)",
                    "guid": "f4a7vg499-Aq2GCLZFQwLw",
                    "children": []
                  },
                  {
                    "id": "283",
                    "parent": "281",
                    "text": "• Alto Riesgo (~25% progresión/año en primeros 2 años)",
                    "guid": "QCYiaAHA75kYlpiIGlLzNw",
                    "children": []
                  }
                ]
              },
              {
                "id": "284",
                "parent": "276",
                "text": "◊ ★ Criterios Alto Riesgo (ej. Mayo 2018: 2 ó 3 de: Prot M >2g/dL, Ratio FLC >20, Cél Plasmáticas MO >20%)",
                "guid": "TcfxBiLDyKkuP6rXTsfX_A",
                "children": []
              },
              {
                "id": "285",
                "parent": "276",
                "text": "◊ Otros factores: Prot M ≥30g/L, Evolución rápida prot M, Cél Plasmáticas MO 50-60%, **t(4:14)/del(17p)/1q gain**,\nCél Plasmáticas Circulantes altas, RM difusa/1 lesión focal, PET-CT lesión focal hipercaptante sin lisis",
                "guid": "Judc2ylMm0lM5dkwJvzLYQ",
                "children": []
              },
              {
                "id": "286",
                "parent": "276",
                "text": "◊ Calculadoras de riesgo (ej. IMWG myelomarisk.com)",
                "guid": "YKM7AijtDAYdPQ2XBnuSbw",
                "children": []
              },
              {
                "id": "287",
                "parent": "276",
                "text": "◊ ★ Tratamiento Preventivo\nSMM Alto Riesgo:",
                "guid": "dNEx4ERO-KZw1ywEHLFsUw",
                "children": [
                  {
                    "id": "288",
                    "parent": "287",
                    "text": "• Estudios iniciales negativos",
                    "guid": "bDrbozy-1e8ScnUkD7Vxyw",
                    "children": []
                  },
                  {
                    "id": "289",
                    "parent": "287",
                    "text": "• Ensayo Español (QuiRedex): **Lenalidomida + Dexametasona (Rd)** mejoró PFS y OS vs observación",
                    "guid": "ZX9bNmld9rJdP7uOZQYW9A",
                    "children": []
                  },
                  {
                    "id": "290",
                    "parent": "287",
                    "text": "• Ensayo **ECOG E3A06**: **Lenalidomida** sola prolongó tiempo a daño orgánico vs observación",
                    "guid": "d5vukggYHBpJWkcjN8IQ-w",
                    "children": []
                  },
                  {
                    "id": "291",
                    "parent": "287",
                    "text": "• ★ Recomendación actual: Considerar **Lenalidomida** o **Rd** por 2 años para SMM Alto Riesgo recién diagnosticado",
                    "guid": "CdkLs2Hw36tSFQQyV6D8uQ",
                    "children": []
                  },
                  {
                    "id": "292",
                    "parent": "287",
                    "text": "• Ensayos en curso (ej. **DRd** vs **Rd**)",
                    "guid": "BLSoVQBUrwkmaNS1K5wFMA",
                    "children": []
                  },
                  {
                    "id": "293",
                    "parent": "287",
                    "text": "• Ensayos de intervención temprana con intención curativa (ej. GEM-CESAR: **KRd** → ASCT → **KRd** → **Rd**)",
                    "guid": "KaFKUnNOreZSmNCSCkSFVQ",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "node_count": 294,
  "relations": [],
  "cross_references": [],
  "specialty": "General",
  "folder": "- Entidades clínicas/Hematología",
  "filename": "Paper. Mieloma Múltiple Actualización-2025",
  "id": "map_1469",
  "resolved_references": []
}